Adverse Reactions To Pfizer Vaccine Weaken Case For India Trial Waiver
Executive Summary
Indian regulator is likely to ask Pfizer/BioNTech to conduct clinical trials before granting an accelerated approval, but recruitment could prove challenging for the COVID-19 vaccine as anaphylactic reactions in the US and UK sparks worry.
You may also be interested in...
Compensation For COVID-19 Vaccine Injuries In India: Stark Fault Lines?
Experts discuss the complexities of pursuing compensation for COVID-19 vaccine-related injuries in India. Is there a case for ‘absolute liability’ for all injuries related to the two fast-tracked vaccines currently available, or alternatively a no-fault compensation program?
H1 Approvals Seen For Russian, Novavax COVID-19 Vaccines In India
Multiple COVID-19 vaccines, including from RDIF and Novavax, could get accelerated approvals in India in the first half of calendar 2021, expanding the range at the country’s disposal. J&J's vaccine is expected to follow although it still hasn’t begun local trials, while Pfizer has temporarily withdrawn an application.
Compensation For COVID-19 Vaccine Injuries In India: Stark Fault Lines?
Scrip discusses with a cross-section of experts the complexities around pursuing compensation for COVID-19 vaccine-related injuries in India. Is there a case for ‘absolute liability’ for all injuries related to the two fast-tracked vaccines currently available, or alternatively a no-fault compensation program?